Short Interest in 111, Inc. (NASDAQ:YI) Drops By 54.5%

111, Inc. (NASDAQ:YI) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 3,000 shares, a decline of 54.5% from the March 15th total of 6,600 shares. Based on an average daily trading volume, of 41,200 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of YI. FIL Ltd bought a new position in 111 during the 4th quarter worth approximately $450,000. Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in 111 in the fourth quarter worth $245,000. Finally, JPMorgan Chase & Co. increased its stake in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after purchasing an additional 305,339 shares during the last quarter. Hedge funds and other institutional investors own 21.32% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 111 in a research report on Tuesday, April 8th.

111 Trading Up 4.1 %

Shares of 111 stock opened at $7.60 on Wednesday. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The stock has a market cap of $65.00 million, a price-to-earnings ratio of -1.90 and a beta of 0.57. The company has a fifty day moving average price of $8.26 and a 200 day moving average price of $7.52.

111 (NASDAQ:YI) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The company had revenue of $527.14 million during the quarter.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.